Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Clinical trial NCT03239145 · COMPLETED

Trial details

NCT number: NCT03239145
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2018-05-01
Primary completion: 2024-12-13
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.